Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? by Denzinger, Stefan et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
World Journal of Surgical Oncology
Open Access Research
Sporadic renal cell carcinoma in young and elderly patients: are 
there different clinicopathological features and disease specific 
survival rates?
Stefan Denzinger*1, Wolfgang Otto1, Maximilian Burger1, 
Christine Hammerschmied1, Kerstin Junker2, Arndt Hartmann3, 
Wolf F Wieland1 and Bernhard Walter1
Address: 1Department of Urology, University of Regensburg, Regensburg, Germany, 2Department of Urology, University of Jena, Germany and 
3Institute of Pathology, University of Regensburg, Regensburg, Germany
Email: Stefan Denzinger* - stefandenzinger@gmx.de; Wolfgang Otto - wolfgang1.otto@klinik.uni-regensburg.de; 
Maximilian Burger - maximilianburger@gmx.de; Christine Hammerschmied - christine.hammerschmied@klinik.uni-regensburg.de; 
Kerstin Junker - Kerstin.Junker@med.uni-jena.de; Arndt Hartmann - arndt.hartmann@klinik.uni-regensburg.de; 
Wolf F Wieland - wieland@caritasstjosef.de; Bernhard Walter - bwalter@caritasstjosef.de
* Corresponding author    
Abstract
Background:  Sporadic renal cell carcinoma (RCC) is rare in young adults. In the present
retrospective study we reviewed clinicopathological features and disease specific survival rates in
young patients (≤45 years) with RCC and compared them to old patients (≥75 years) with RCC.
Methods:  Between 1992 and 2005 a total of 1042 patients were treated for RCC at our
institution. We found 70 patients 45 years or younger (YP) and 150 patients 75 years or older (OP)
at time of diagnosis. There were no differences in therapeutical approaches between both groups.
Clinical and biologic parameters at diagnosis were compared and subjected to uni- and multivariate
analysis to study cancer specific survival and progression rate. Mean postoperative follow-up in
both groups was 50.1 months.
Results:  Mean age was 39 years in YP and 80 years in OP, respectively. YP demonstrated
significantly lower stage (pT1-pT2 N0 M0, p = 0.03), lower tumor grade (p = 0.01) and higher male-
to-female ratio (p < 0.001). The rate of lymph node metastases or distant metastatic disease at
presentation did not differ significantly between both groups. In multivariate analysis young age was
independently associated with a higher 5-year cancer specific survival (95.2% vs. 72.3%, p = 0.009)
and a lower 5-year progression rate (11.3% vs. 42.5%, p = 0.002).
Conclusion: Sporadic RCC in young patients have lower tumor stages and grades and a better
outcome compared to elderly. Age≤45 years was an independent prognostic factor for survival and
progression.
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Background
Renal cell carcinoma (RCC) is the most common renal
parenchymal malignancy and represents 3% – 6% of all
adult malignancies [1]. Patients are generally older than
40 years at diagnosis and the disease occurs predomi-
nantly in the seventh decade of life [2]. Only 3 to 7% of
all sporadic RCC patients have been reported to be below
40 years [3-7].
In other tumor entities it has been noted that younger
adults often have a less favorable prognosis than elderly
patients. Solid organ malignancies including those of
breast, colorectal and prostate in young patients have
been already investigated [8-11] and these tumors seem to
have a more pejorative survival prognosis. There have
been anecdotal reports that renal masses may behave in a
more biologically aggressive manner with poorer out-
comes in younger patients [3,6]. To date, the rare studies
on early onset RCC have been mostly descriptive with a
small number of patients and a relatively short follow-up
(table 1) [3,5,12-19]. Some studies lack a group of regular
onset patients for comparison at all [12,13]. Many data
are conflicting however and study designs vary considera-
bly as well. In analogy to these conflicting data, major dif-
ferences in methodology are found in the data published
to date. In the present retrospective study we compare
clinicopathological features and cancer specific survival of
patients with confirmed RCC aged 45 years or younger
with patients 75 years or older in univariate and multivar-
iate analysis. By setting a minimum of 30 years between
the groups we hoped to increase the discrimination and to
shed further light on the clinical behavior of young versus
old patients with RCC.
Methods
Between 1992 and 2005 a total of 1042 patients under-
went partial or radical nephrectomy for renal masses at
the Department of Urology of the University of Regens-
burg. The medical and histopathological data of 70 YP
(range: 26 to 45 years, mean: 39 years) and 150 OP
(range: 75 to 91 years, mean: 80 years) suffering from
RCC were reviewed We did not include middle-aged
patients (>45 years and < 75 years) to avoid masking any
potential differences in tumor biology between young and
old patients. All familial RCC syndromes including von
Hippel-Lindau disease were excluded. Pathological evalu-
ation was reviewed and tumor stage was adapted accord-
ing to the 2002 TNM classification. Patients were
evaluated preoperatively by physical examination, labora-
tory studies, ultrasonography and radiographic staging
including chest x-ray and computerized tomography.
Staging lymph nodes dissection was performed for all
patients. The postoperative outcomes and duration of fol-
low-up were compiled by chart review and patient inter-
view. Complete follow-up information was available for
all patients through a department registry. Statistical anal-
ysis were completed using SPSS version 12.0 (SPSS, Chi-
cago, IL). Contingency table analysis and two-sided
Fisher's exact tests were used to study the statistical associ-
ation between the two groups. Significant differences con-
cerning tumor progression and cancer specific survival
were calculated using the Kaplan-Meier method and log
rank test. For cancer related death, patients were surveyed
at the time of their last clinical follow-up appointment or
at their date of death not related to the tumor. Deaths
from causes other than RCC were censored. Uni- and mul-
tivariate Cox proportional hazards models were per-
formed to evaluate the relationship between cancer
specific survival, tumor progression, TNM pathologic
stage, histologic subtypes, tumor grade, incidental or
symptomatic disease and, in addition to other variables,
age (separated into YP and OP). P values < 0.05 were con-
sidered significant.
Results
Comparison of histopathological and clinical parameters 
according to age
Epidemiology
Of the 86 young patients undergoing renal surgery, 70
(81.3%) were treated for RCC, 15 (17.5%) for benign
lesions like oncocytoma and angiomyolipoma and one
(1.2%) for lymphoma. Within consecutively chosen 179
older patients RCC dominated with 150 (83.8%) cases,
benign renal masses were found in 28 (15.6%) patients
and leiomyosarcoma in one patient (0.6%). While the
expected sex ratio was seen in YP with 76% male patients,
it was reversed in OP (43%; p < 0.001) (table 2).
Etiology
YP were more likely to smoke tobacco (>10 cigarettes per
day, 46.3% vs. 9.7%, p < 0.001) but did not differ con-
cerning obesity (BMI >30; 20.9% vs. 22.1%, p = 0.93).
There were no significant differences in the rate of second-
ary malignancies (p = 0.07).
Clinical presentation
RCC was an incidental finding in 71.6% YP and 65.5%
OP (p = 0.19). In both groups dominant symptoms were
flank pain (17.9% vs. 12.4%, p = 0.23) and macroscopic
hematuria (13.1% vs. 10.4%, p = 0.43). While there was a
tendency for OP to present more often with fever, night
sweat or loss of weight (11.7% vs. 4.5%), this failed to
reach the level of significance (p = 0.09). The rate of
lymph node metastases (YP: 3.2%, OP: 8.7%, p = 0.24) or
distant metastatic disease (YP: 1.8%, OP: 5.6%, p = 0.71)
at presentation did not differ significantly between both
groups.World Journal of Surgical Oncology 2007, 5:16 http://www.wjso.com/content/5/1/16
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Histopathological features
YP showed significantly lower T stage (p = 0.03) and
tumor grade (p = 0.01). While chromophobe RCC was
more frequent in OP, this failed to reach the level of sig-
nificance (10.7% vs. 7.1%, p = 0.32). There were no statis-
tically significant differences in tumor location and
focality, mean tumor diameter (YP: 6.5 cm, OP: 7.3 cm, p
= 0.39), WHO 2002 N and M stages or UICC stage (table
2).
Therapy
Nephron sparing approach was chosen more often in YP
(19.4% vs. 9.0%, p = 0.031). A similar proportion of
patients in the two groups with nodal or distant metasta-
Table 2: Comparison of clinical and pathological features of young (YP) and elderly (OP) RCC patients.
YP (70 patients) No. (%) OP (150 patients) No. (%) p Value
Sex < 0.001
Female 17 (24%) 86 (57%)
Male 53 (76%) 64 (43%)
Sex ratio (male/female) 3.1 0.7
Clinical presentation p = 0.19
Symptomatic 20 (28.4%) 52 (34,5%)
Asymptomatic 50 (71.6%) 98 (65.5%)
WHO 2002 stage of primary tumor p = 0.03
pT1- pT2, N0, M0 60 (85.7%) 101 (67.3%)
pT3, N0, M0 7 (10.0%) 29 (19.3%)
pT4 and/or N+, and/or M+ 3 (4.3%) 20 (13.4%)
Tumor grade p = 0.01
Grade 1 24 (34,3%) 24 (16.0%)
Grade 2 35 (50.0%) 110 (73.3%)
Grade 3 11 (15.7%) 16 (10.7%)
RCC subtypes: p = 0.32
Clearcell RCC 47 (67.2%) 98 (65.3%)
Papillary RCC 13 (18.6%) 29 (19.4%)
Chromophobe RCC 5 (7.1%) 16 (10.7%)
Other histological types 5 (7.1%) 7 (4.6%)
bold face representing p-values < 0.05
RCC = renal cell carcinoma
Table 1: Previous RCC studies and cancer specific survival rates of young and old RCC patients.
Study Study period Young group Older group 5-year cancer specific survival rate p Value
No. patients Mean age No. patients Mean age Young Old
Boykin et al. [3] 1947–1989 14 *** *** 70% ***
Abou El Fettouh et al. [12] 1981–2001 101 33.7 y *** *** 67% ***
Eggener et al. [13] 1988–2002 91 37.1 y *** *** 88% ***
Schiff et al. [5] 1948–1980 37 31.0 y 486 (≥41 y) *** 92%* 45%* p < 0.01
Rainwater et al. [14] 1970–1986 41 35.7 y 34 (≥80 y) 82.4 y 74% 70% n.s.
Yusim et al. [14] 1985–1997 15 37.0 y 107 (≥50 y) 63.0 y 93% 77% p < 0.05
Gillett et al. [16] 1970–2000 107 *** 958 (60–70 y) *** 75%** 72%** n.s.
Goetzl et al. [17] 1989–2002 34 35.0 y 99 (≥41 y) 65.0 y 85% 84% n.s.
Sanchez-Ortiz et al. [18] 1992–2002 106 34.7 y 145 (58–61 y) 59.4 y 66% 52% p < 0.01
Siemer et al. [19] 1975–2004 87 34.1 y 2164 (≥41 y) *** 78% 72% n.s.
* only of stage I RCC
** only of clear cell RCC
*** no data available
y = years
n.s. = not significant (p < 0.05)World Journal of Surgical Oncology 2007, 5:16 http://www.wjso.com/content/5/1/16
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sis received additional therapy (immunotherapy, tumor
vaccines or conventional chemotherapy). There were no
differences in mean tumor size, tumor location, perform-
ance status, ethnicity, family history of cancer, body mass
index or type of treatment between YP and OP cohort.
Predictive parameters for cancer specific survival
Mean postoperative follow-up was 52.1 months in YP and
49.4 months in OP. Table 3 shows univariate Cox regres-
sion analysis to evaluate the relationship between clinical
and pathological variables and cancer specific survival. In
this setting, the following prognostic factors were found:
age, TNM stage, nodal status, M status, grade and clinical
presentation. In addition no significant survival difference
were found according to sex and histological subtypes.
Young age emerged as an independent predictor of
improved survival on multivariate analysis (adjusted HR
0.21, 95% CI 0.11 – 0.89, p = 0.03, table 4).
Of the 70 YP three died of RCC at a mean of 3.8 years after
nephrectomy. Of the 150 OP 15 died at a mean of 3.4
years following nephrectomy. One patient in YP and 23 in
OP died of causes other than RCC. Kaplan-Meier survival
analysis revealed a 5-year cancer specific survival rate of
95.2% for YP compared with 72.3% for OP. Log rank test
did show a significantly better cancer specific survival for
YP (p = 0.009; figure 1). OP more often developed sys-
temic progress (OP: 15.3% vs. YP: 4.3%), mostly pulmo-
nary and hepatic metastasis. The 5-year progression rate
was 14.2% for YP and 41.9% for OP (log rank p = 0.002;
figure 2).
Discussion
Just 3.4% to 7.5% of all RCC patients have been reported
to be young adults [7]. This is reflected in our series, as
7.2% of 968 RCC patients were aged ≤45 years. It has been
suspected that young RCC is characterized by different
clinicopathological and biologic character. However pre-
vious studies are somewhat contradictory and feature var-
ious methodologies. Some previous studies lack a
Table 3: Univariate Cox regression analysis of factors possibly influencing cancer specific survival in patients with RCC.
HR 95% CI P
Age 0.02
YP (≤45 years) 0.37 0.15 – 0.72
OP (≥75 years) 1.00 (reference)
pTNM stage 0.002
pT1+pT2 1.00 (reference)
pT3 +pT4 3.46 1.72 – 12.49
Nodal status < 0.001
N0 1.00 (reference)
N1, N2 5.57 1.98 – 15.64
M status < 0.001
M0 1.00 (reference)
M1 35.99 9.88 – 131.02
Tumor grade < 0.001
G1+G2 1.00 (reference)
G3 4.01 0.73 – 21.94
Tumor diameter < 0.01
< 7 cm 1.00 (reference)
≥7 cm 1.76 0.40 – 10.38
Histological subtype
Clear-cell 1.00 (reference)
Papillary 1.43 0.46 – 4.97 0.54
Chromophobe 1.06 0.23 – 4.78 0.92
Other histological types 1.15 0.15 – 8.96 0.89
Sex
Male 1.00 (reference)
Female 0.61 0.24 – 1.56 0.29
Clinical presentation 0.002
Asymptomatic 1.00 (reference)
Symptomatic 4.41 1.71 – 11.37
bold face representing p-values < 0.05
HR = hazard ratio
CI = confidence interval
RCC = renal cell carcinomaWorld Journal of Surgical Oncology 2007, 5:16 http://www.wjso.com/content/5/1/16
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pronounced span of age between young patients and the
comparison group. While 20 years were chosen by Gillett
[16], Sanchez-Ortiz chose 18 years [18], but even less has
been employed [5,15,17,19]. To compare YP and OP we
have determined a minimum of 30 years separating both
groups. We thus hoped to increase the discrimination
between young and old patients, as some overlap might
occur blurring the picture. This approach seems to be
backed up by epidemiological data suggesting a signifi-
cantly lower incidence in patients aged up to 45 years [2].
OP were a mean 8 years above the major age of regular
onset, which has been reported to be roughly 70 [2]. Thus
while it has to be taken into consideration, that OP might
somewhat differ from regular onset patients, the present
series offers a clear separation between OP and YP. Analy-
sis of our population confirmed the usual prognostic fac-
tors for RCC: pTNM tumor stage, tumor grade, tumor
diameter, N and M stage and circumstances of renal cell
carcinoma discovery. Contrary to expectations, symptoms
that may be considered as substitutes for performances
status were not retained as independent prognostic factors
in our multivariate analysis. Moreover, recent studies con-
sidering this parameter did not show any difference
according to the age at diagnosis [16,18]. Controversial
data exist on the histopathological character of younger
patients. In the present series YP clearly demonstrated
lower T stages and lower tumor grade (table 2), while
other studies only showed lower T stages in YP
[6,16,18,19]. Schiff et al. compared patients younger than
40 years old to patients older than 40 years. Their data dif-
fered with the most contemporary series in that more
patients in the older group presented with T1 tumors [5].
Table 4: Multivariate Cox regression analysis of factors possibly influencing cancer specific survival in patients with RCC.
stepwise reverse selection
adjusted HR 95% CI P
Age 0.03
YP (≤45 years) 0.21 0.11 – 0.89
OP (≥75 years) 1.00 (reference)
pTNM stage 0.01
pT1+pT2 1.00 (reference)
pT3+pT4 2.82 0.74 – 10.49
Nodal status 0.04
N0 1.00 (reference)
N1, N2 2.37 0.95 – 5.69
M status < 0.001
M0 1.00 (reference)
M1 20.61 3.32 – 127.78
Grade < 0.001
G1+G2 1.00 (reference)
G3 1.65 0.18 – 15.08
Tumor diameter < 0.01
< 7 cm 1.00 (reference)
≥7 cm 1.88 0.46 – 11.18
Histological subtype
Clear-cell 1.00 (reference)
Papillary 0.78 0.14 – 3.48 0.67
Chromophobe 1.02 0.21 – 5.75 0.90
Other histological types 0.68 0.06 – 6.56 0.71
Sex
Male 1.00 (reference)
Female 0.52 0.38 – 2.01 0.35
Clinical presentation
Asymptomatic 1.00 (reference)
Symptomatic 0.67 0.09 – 2.33 0.49
bold face representing p-values < 0.05
HR = hazard ratio
CI = confidence interval
RCC = renal cell carcinomaWorld Journal of Surgical Oncology 2007, 5:16 http://www.wjso.com/content/5/1/16
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In contrast to our series a former study of wide span com-
parison of RCC patients < 40 years and >80 years could
not figure out any differences in tumor grade [14]. A vari-
ation of distribution of histological subtypes has been
reported by Gillett et al. In their to date largest series of
107 younger cases chromophobe RCC were found in
13.1% vs. 3.6% [16]. Also Rodriguez et al. found out dif-
ferences in histological subtypes, OP significantly more
often showed clear cell RCC than YP (91.0% vs. 69.0%, p
< 0.001) [6]. In accordance with previous reports [16-19]
in our series however there was an even distribution of
subtypes among YP and OP. Previous authors have sug-
gested that younger adults may have more aggressive renal
tumors with a poorer prognosis than older patients [3,6].
YP tended to improved cancer specific survival in the
present series. 5-year survival rate was 95.2% in YP and
72.3% in OP (p = 0.009). This finding supports previous
reports [5,15], also in non comparative studies young
patients showed similar survival rates [3,12,13], and is in
analogy to favourable histopathology in YP. The less
advanced forms of RCC found in YP may explain the bet-
ter 5- year cancer specific survival. Several earlier studies
[5,6] had reported comparable survival rates, despite their
higher percentages of localised forms in young patients,
suggesting that early-onset RCC forms might be more
aggressive. However, those studies had short follow-up
[17] or had small population size [5], hereby rendering
interpretation of their results more difficult. In the present
series, young age was an independent predictor of
improved cancer specific survival. Siemer et al. found
young patients to present with symptoms more often.
While in their series young RCC was still related to favour-
able outcome, symptoms caused by malign renal masses
were associated with poor prognosis [19,21]. In our series
YP did not complain of symptoms more often. In synopsis
the factors that determine the improved survival outcome
in YP with RCC have yet to be clearly defined.
We do not believe in profoundly different tumor charac-
ters per se. This notion is supported by a significant
number of young patients presenting with advanced dis-
ease and tumor related death in this group. However we
suspect a reduced momentum of tumor biology in young
patients. We hypothesize a better tumor control, which
might be due to a superior immunology in this age group
slowing the tumors in growth.
Conclusion
To conclude RCC in younger and elder patients, as
defined by a minimum of 30 years as discriminatory span,
young patients present with favourable clinicopathology
and an improved cancer specific 5-year survival rate after
adjusting for clinical and pathological variables on multi-
variate analysis. These obvious differences contribute to
the trend toward improve outcome in younger patients
Kaplan-Meier analysis of cancer progression for YP (= blue  line) vs. OP (= red line) with RCC Figure 2
Kaplan-Meier analysis of cancer progression for YP (= blue 
line) vs. OP (= red line) with RCC.
Kaplan-Meier analysis of cancer specific survival for YP (=  blue line) vs. OP (= red line) with RCC Figure 1
Kaplan-Meier analysis of cancer specific survival for YP (= 
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for which their young age was an independent prognostic
factor. Our data refute past reports of poorer cancer spe-
cific survival in younger patients with RCC.
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